See us on:

As a biotech region, Berlin ranks among the leaders in Europe. 230 biotech companies with about 5,300 employees research and develop new products and processes, particularly in the field of red biotechnology. To name but a few examples, successful companies like Epigenomics, Glycotope, JPT Peptide Technologies, Metanomics, MOLOGEN, NOXXON, ProBioGen and ifp Institut für Produktqualität are all located in Berlin.

But there are other advantages, too. A strong group of closely networked, research-based pharmaceutical companies includes major international players like Bausch + Lomb, Bayer AG, Berlin-Chemie (Menarini Group), Pfizer, Sanofi and Takeda.

The city is unique in Europe for its many independent research institutions working outside of a university context. Nowhere else is such variety to be found in such concentration, and nowhere else is research performed at such levels of excellence. Together, these institutes provide an exceptional platform for innovation, which is aided further by their close ties to partners in the industry.

Moreover, the capital’s over 130 hospitals and contract research organizations (CROs) provide excellent opportunities for collaborating on clinical studies.

Why Berlin?

Günter Kloucek

»As an international company we want to be present in Berlin. Takeda is the largest pharmaceutical company in Japan and Berlin offers us many benefits at once: Proximity to the government, to our business association (vfa) and also to other pharmaceutical companies.«

Günter Kloucek, General Manager, Takeda Pharma Vertrieb GmbH & Co. KG